Over the years there has been a lot of talk about vaccines and particularly Dendreon's Provenge. Follows is the latest development.
The Advisory panel of the FDA has voted in support of releasing Provenge. This is not binding on the FDA itself—they can accept or reject the panels findings. There are some rather serious questions about the use of the drug and the results.
On average in the small sample of men in the study it extended their life by not much. That worked out to 4.5 months of extra survival—25.9 months for those receiving Provenge vs. 22 months for those not taking the vaccine. One has to wonder about the quality of life in those extra 4.5 months. This was for patients who no longer responded to Hormonal Ablation Therapy (HT).
In the two studies involved (another one is underway) they were not able to show that it prevented progression of the disease.
Read full story in Prostate Help.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment